Adjunctive Inhaled Colistin for Respiratory Infections
For respiratory infections caused by multidrug-resistant gram-negative organisms requiring IV colistin, add adjunctive nebulized colistin to the intravenous regimen 1, 2. This combination approach reduces clinical treatment failure and improves microbiological eradication compared to IV therapy alone.
Evidence-Based Recommendation
The most recent guidelines (2023) provide a weak recommendation for adding aerosolized polymyxin to IV polymyxin in patients with carbapenem-resistant gram-negative bacilli (CRGNB) respiratory tract infections 2. The 2016 IDSA/ATS guidelines similarly suggest adjunctive inhaled colistin for HAP/VAP caused by organisms sensitive only to polymyxins 1.
Key clinical benefits of combination therapy include:
- 77 fewer clinical treatment failures per 1000 patients (RR 0.82,95% CI 0.70-0.96) 2
- 50 fewer deaths per 1000 patients (RR 0.86,95% CI 0.72-1.03) 2
- 62 fewer pathogen eradication failures per 1000 patients (RR 0.84,95% CI 0.69-1.03) 2
- Higher clinical cure rates (77.1% vs 59.6%) and microbiological clearance (60.4% vs 39.3%) 3
Dosing Recommendations
Intravenous Colistin (Colistimethate Sodium)
Standard dosing: 2.5-5 mg/kg/day of colistin base activity divided into 2-4 doses for patients with normal renal function 4, 5
Loading dose is essential due to slow conversion of colistimethate to active colistin - administer one-half of total daily dose over 3-5 minutes initially 4, 5, 6
Renal adjustment required:
- CrCl 50-79 mL/min: 2.5-3.8 mg/kg divided into 2 doses
- CrCl 30-49 mL/min: 2.5 mg/kg once daily or divided into 2 doses
- CrCl 10-29 mL/min: 1.5 mg/kg every 36 hours 4, 5
Nebulized Colistin
Dosing: 50 mg (range typically 50-150 mg) twice daily via nebulization 2, 3, 7
Administration details:
- Use colistimethate sodium (CMS) - preferred formulation for inhalation 2
- Reconstitute 150 mg vial with 2 mL sterile water to achieve 75 mg/mL concentration 4, 5
- Administer promptly after mixing - FDA warning against premixed formulations 1
- Deliver via vibrating mesh nebulizer (preferred - delivers 35.68% dose) or jet nebulizer (delivers 23.56% dose) 8
- For ventilated patients: position nebulizer at humidifier inlet for optimal delivery 8
When to Use Combination Therapy
Primary indications:
- HAP/VAP caused by Acinetobacter species sensitive only to polymyxins 1
- Carbapenem-resistant Enterobacteriaceae (CRE) pneumonia sensitive only to polymyxins 1
- Any CRGNB respiratory infection when clinical efficacy with IV alone is suboptimal 2
Important caveat: Aerosolized polymyxin is generally not used as monotherapy - always combine with IV therapy 2
Safety and Monitoring
Nephrotoxicity profile:
- IV alone: 23.3% incidence 9
- IV + inhaled: 13.3-15% incidence 3, 9
- The combination may actually reduce nephrotoxicity risk compared to IV monotherapy 10
Respiratory adverse events to monitor:
- Bronchospasm: 7.5-13% incidence 2, 3, 7
- Alveolar hemorrhage: rare but reported 11
- Monitor closely during initial administrations
Therapeutic drug monitoring warranted due to high interpatient variability in plasma colistin concentrations 6
Treatment Duration
Standard course: 7 days for both HAP and VAP 1
Adjust duration based on clinical, radiologic, and laboratory response - some situations may require shorter or longer courses 1
Critical Pitfalls to Avoid
- Never skip the loading dose - colistimethate converts slowly to active colistin, delaying therapeutic levels 6
- Do not use premixed colistin solutions - FDA warning after patient death; mix fresh before each administration 1
- Adjust for renal function - failure to dose-reduce increases nephrotoxicity risk without improving outcomes 4, 5
- Consider combination therapy when MIC >1 mg/L - increasing IV dose alone may not be feasible due to toxicity 6
- Use within 24 hours - any IV infusion solution containing colistimethate must be freshly prepared 4, 5
Practical Algorithm
Step 1: Confirm MDR gram-negative organism sensitive only to colistin/polymyxins
Step 2: Initiate IV colistin with proper loading dose (half of daily dose over 3-5 minutes)
Step 3: Add nebulized colistin 50 mg twice daily within first 24 hours
Step 4: Monitor for bronchospasm during first 2-3 nebulization sessions
Step 5: Check renal function every 2-3 days; adjust IV dose accordingly
Step 6: Assess clinical response at days 2,5, and 7-10
Step 7: Complete 7-day course unless clinical parameters dictate otherwise
The evidence consistently demonstrates that combination IV plus inhaled colistin provides superior outcomes with acceptable safety compared to IV monotherapy for MDR gram-negative respiratory infections 10, 3, 12, 7.